Fusion Pharmaceuticals  logo
Fusion Pharmaceuticals FUSN

Quarterly report 2024-Q1
added 05-07-2024

report update icon

Fusion Pharmaceuticals Revenue 2011-2026 | FUSN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Fusion Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
2.07 M 1.46 M 1.44 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.07 M 1.44 M 1.66 M

Quarterly Revenue Fusion Pharmaceuticals

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - 2.01 M 34 K 28 K - 166 K 570 K 585 K - 325 K 521 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.01 M 28 K 529 K

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
238 M - 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
118 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
1 M - - $ 86.2 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
958 M $ 22.56 2.13 % $ 3.74 B usaUSA
AlloVir AlloVir
ALVR
165 K - 4.14 % $ 49.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
9.99 M - - $ 8.42 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
236 M $ 1.43 3.62 % $ 368 M usaUSA
argenx SE argenx SE
ARGX
36.4 M $ 785.07 2.57 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
88 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
6.07 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
70.9 M - 2.54 % $ 160 B franceFrance
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
3.71 B $ 327.25 2.42 % $ 42.9 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
66.4 M $ 2.66 3.5 % $ 16.7 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
692 K - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
58.7 B - - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
381 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 K - -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
5.34 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
109 K $ 3.9 3.7 % $ 9.38 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
31.1 M - - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
720 M $ 20.4 -0.87 % $ 954 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
44.5 M $ 4.18 1.21 % $ 447 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
140 M - - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
1.28 M - - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.08 B - - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
376 M $ 24.61 5.76 % $ 3.13 B usaUSA
Cabaletta Bio Cabaletta Bio
CABA
0.006 $ 3.09 0.65 % $ 310 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
41 K - - $ 169 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
9.59 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
130 K - -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
7.9 M - - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
886 K - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
325 K - - $ 26.5 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
75.4 M $ 1.49 9.56 % $ 397 M britainBritain
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
53.9 M - - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
123 M - 1.93 % $ 17.4 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
43 K - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
163 M - - $ 2.18 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
277 M - - $ 2.02 B usaUSA
Forte Biosciences Forte Biosciences
FBRX
18 M $ 26.27 0.38 % $ 340 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
48.9 M - - $ 867 M germanyGermany